Mankind Pharma Ltd announced its financial results for the fourth quarter and full year ended 31st March 2025. A) For Q4 FY25 a) Revenues = Rs 3,079 Crore b) Domestic Revenue = Rs 2,544 Crore c) Adjusted EBITDA = Rs 711 Crore B) For FY25 a) Revenues = Rs. 12,207 Crore ( 19% YoY) b) Domestic Revenue = Rs 10,675 Crore (13% YoY) c) Adj. EBITDA = Rs 3,159 Crore (26% Margin) Mr. Rajeev Juneja – Vice Chairman & Managing DirectorM commented " Mankind’s revenue grew by 27% with adjusted EBITDA margins at ~23% in Q4 FY25 led by continued 1.3x outperformance in Chronic, strong growth in Consumer segment and BSV "

#StockInNews#WatchOutFor

105 likes·44 comments